With respect to Ampio, it is clear that racavalli has been promoting the simple truth in his factual representations. Whatever one may have thought about his personal beliefs as to where the stock price is going and when, his presentation of the widely available materials scattered on the Internet, combined with any personal research he may have done, allowed him to make a strong case for investment in Ampio.
We all know that it is currently a small company and hence a speculative investment. It is, nonetheless, not overburdened with "ifs" and "maybes" and the "I believes" we so often hear. The "story" on Ampio is largely grounded in the caliber of its leadership, the true value of its concrete progress with several drugs, and the research and development capability of its scientists.
You may have found Cavalli overly repetitive, even to the point of being boring. However, I do not believe you can find anything but a strict adherence to the truth in his factual assertions about the company, its results to date, its clearly defined pathway, and its future potential. The FDA meeting is of enormous significance.
Regarding the company's going into production with Ampion, why wouldn't they? Don't you imagine, as I do, that any number of countries would be satisfied with the duplication of the Australian results in the recent trial and would give the go-ahead for their physicians to start writing prescriptions ASAP? Moreover, Ampion is the one drug that Ampio should try to keep entirely for itself. There are so many more applications beyond simply OA of the knee.
The announcement today that they have secured a long term supply of human serum albumen shows that they are well on their way to manufacturing AMPION themselves. This will put them in a much stronger position of strength when they eventually negotiate a deal with Big Pharma. The margings on making AMPION should be huge. They will ask to not have to do a further Phase 3 trial at the FDA meeting due to the tremendous results of the prior trial, and a large unmet immediate need for their drug by patients.